Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
5.10
-0.16 (-3.04%)
At close: Mar 28, 2025, 4:00 PM
5.12
+0.02 (0.41%)
After-hours: Mar 28, 2025, 7:51 PM EDT
Monte Rosa Therapeutics Revenue
In the year 2024, Monte Rosa Therapeutics had annual revenue of $75.62M. Monte Rosa Therapeutics had revenue of $60.65M in the quarter ending December 31, 2024.
Revenue (ttm)
$75.62M
Revenue Growth
n/a
P/S Ratio
4.98
Revenue / Employee
$564,343
Employees
134
Market Cap
313.70M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GLUE News
- 10 days ago - Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - GlobeNewsWire
- 19 days ago - Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - GlobeNewsWire
- 4 weeks ago - Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 6 weeks ago - Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN - Seeking Alpha
- 2 months ago - Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - GlobeNewsWire